What is 503B compounding insurance?

A 503B outsourcing facility manufactures sterile compounded preparations for hospital and clinic administration and is registered with FDA under a different regulatory regime than 503A pharmacies - closer to small-molecule drug manufacturing than to traditional pharmacy compounding. The insurance program reflects this: it sits closer to a CDMO program than to a community pharmacy program.

Core components: products liability ($5M-$10M typical, scaled by hospital purchase contract demand), druggist professional liability ($1M-$3M for individual prescription errors), recall coverage (first-party, $1M-$10M), cGMP property and business interruption (validation losses are a distinct exposure), cyber/HIPAA (PHI exposure is high), and D&O for the operating entity.

Hospital purchase contracts and GPO supplier agreements (Vizient, Premier, HealthTrust) demand named-additional-insured for the hospital and GPO on a primary/non-contributory basis, waiver of subrogation, 30-day notice of cancellation, and explicit FDA recall extension. The schedule is enforced through automated credentialing platforms (Symplr, Reptrax, Vendormate) which block hospital purchases when COIs do not match line by line.

For Texas 503Bs, the relevant hospital systems (HCA, Memorial Hermann, Houston Methodist, Texas Medical Center anchors) each have slightly different schedule demands. Program design that satisfies the most demanding schedule generally satisfies the others.